Numerous data offered significant evidence that both CD36 and CD47 converge by binding to TSP-1, towards an anti-angiogenic effect, which points to this triad as effective adjuvant therapy for aggressive solid tumors, such as GBM. The gene discussed is CD47; the disease is glioblastoma.